ANCA-associated vasculitis, or AAV, is part of a group of rare autoimmune conditions that cause small blood vessel inflammation and damage, with approximately 70% of patients experiencing kidney involvement. Because of the significant mortality risk associated with each disease relapse, which leads to cumulative organ damage, timely diagnosis and early intervention are critical to improving patient outcomes. Through patient perspectives and case-based discussions, participants will explore early intervention strategies, the latest clinical practice guidelines (KDIGO and EULAR), and the role of newer therapeutic options for both short- and long-term management. Special emphasis will be placed on the importance of preserving kidney function through optimal induction and maintenance strategies to achieve optimal outcomes for patients with AAV.
Click here to register for the ERA Congress.
The ERA assumes no responsibility for the information published on this website.
Preserving Renal Function in AAV: From Novel Therapies to Practice-Changing Strategies
Learn how novel therapies in AAV can mitigate the burden of disease and affect remission and kidney function, plus hear practice-changing strategies.
Bruno-Kreisky-Platz 1, 1220 Wien, Austria, Room B (Level 2)
Overview
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Chair:
David R. W. Jayne, MD, FRCP, FRCPE, FMedSci
Professor of Clinical Autoimmunity
Department of Medicine
University of Cambridge
Cambridge, UK
Dr. Jayne has reported the following relevant financial relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Amgen, AstraZeneca, CSL Vifor, GSK, Novartis, Otsuka
Ownership: Alentis, Aurinia
Research: CSL Vifor
Faculty:
Rachel B. Jones, MD
Consultant in Nephrology and Vasculitis
Cambridge University Hospitals NHS Foundation Trust
Cambridge, UK
Dr. Jones has no relevant relationships to disclose.
Andreas Kronbichler, MD
Assistant Professor
Medical University Innsbruck
Innsbruck, Austria
Dr. Kronbichler has no relevant relationships to disclose.
Reviewers/Content Planners/Authors:- Cindy Davidson has no relevant relationships to disclose.
- Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose.
- Kathleen Sheridan, PhD, has no relevant relationships to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Discuss long-term outcomes of kidney function in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)
- Implement strategies to mitigate the burden of AAV and preserve kidney function
- Develop personalized evidence-based induction and maintenance treatment plans for patients with AAV to achieve sustained remission and prevent relapse
Target Audience
This activity has been designed to meet the educational needs of nephrologists as well as all other physicians, nurse practitioners, nurses, and healthcare providers involved in managing patients with ANCA-associated vasculitis (AAV).
Accreditation and Credit Designation Statements
EBAC® holds an agreement on mutual recognition of substantive equivalency with the US Accreditation Council for CME (ACCME) and the Royal College of Physicians and Surgeons of Canada, respectively.
Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals and the American Medical Association, physicians may convert EBAC® CE credits/points to AMA PRA Category 1 Credits™. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit.
EBAC® is a member of the International Academy for CPD Accreditation (IACPDA) and a partner member of the International Association of Medical Regulatory Authorities (IAMRA).
This live activity is accredited by the European Board for Accreditation of Continuing Education for Health Professional (EBAC) for 60 minutes of effective education time.Provider(s)/Educational Partner(s)
Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.Commercial Support
This activity is supported by an independent educational grant from CSL Vifor.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.ADA Statement
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Andrea Mathis prior to the live event at amathis@glc.healthcare.
Overview
ANCA-associated vasculitis, or AAV, is part of a group of rare autoimmune conditions that cause small blood vessel inflammation and damage, with approximately 70% of patients experiencing kidney involvement. Because of the significant mortality risk associated with each disease relapse, which leads to cumulative organ damage, timely diagnosis and early intervention are critical to improving patient outcomes. Through patient perspectives and case-based discussions, participants will explore early intervention strategies, the latest clinical practice guidelines (KDIGO and EULAR), and the role of newer therapeutic options for both short- and long-term management. Special emphasis will be placed on the importance of preserving kidney function through optimal induction and maintenance strategies to achieve optimal outcomes for patients with AAV.
Click here to register for the ERA Congress.
The ERA assumes no responsibility for the information published on this website.Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Chair:
David R. W. Jayne, MD, FRCP, FRCPE, FMedSci
Professor of Clinical Autoimmunity
Department of Medicine
University of Cambridge
Cambridge, UK
Dr. Jayne has reported the following relevant financial relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Amgen, AstraZeneca, CSL Vifor, GSK, Novartis, Otsuka
Ownership: Alentis, Aurinia
Research: CSL Vifor
Faculty:
Rachel B. Jones, MD
Consultant in Nephrology and Vasculitis
Cambridge University Hospitals NHS Foundation Trust
Cambridge, UK
Dr. Jones has no relevant relationships to disclose.
Andreas Kronbichler, MD
Assistant Professor
Medical University Innsbruck
Innsbruck, Austria
Dr. Kronbichler has no relevant relationships to disclose.
Reviewers/Content Planners/Authors:- Cindy Davidson has no relevant relationships to disclose.
- Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose.
- Kathleen Sheridan, PhD, has no relevant relationships to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Discuss long-term outcomes of kidney function in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)
- Implement strategies to mitigate the burden of AAV and preserve kidney function
- Develop personalized evidence-based induction and maintenance treatment plans for patients with AAV to achieve sustained remission and prevent relapse
Target Audience
This activity has been designed to meet the educational needs of nephrologists as well as all other physicians, nurse practitioners, nurses, and healthcare providers involved in managing patients with ANCA-associated vasculitis (AAV).
Accreditation and Credit Designation Statements
EBAC® holds an agreement on mutual recognition of substantive equivalency with the US Accreditation Council for CME (ACCME) and the Royal College of Physicians and Surgeons of Canada, respectively.
Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals and the American Medical Association, physicians may convert EBAC® CE credits/points to AMA PRA Category 1 Credits™. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit.
EBAC® is a member of the International Academy for CPD Accreditation (IACPDA) and a partner member of the International Association of Medical Regulatory Authorities (IAMRA).
This live activity is accredited by the European Board for Accreditation of Continuing Education for Health Professional (EBAC) for 60 minutes of effective education time.Provider(s)/Educational Partner(s)
Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.Commercial Support
This activity is supported by an independent educational grant from CSL Vifor.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.ADA Statement
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Andrea Mathis prior to the live event at amathis@glc.healthcare.
Recommended
Pearls of Wisdom: Optimizing Hyperkalemia Management in Patients with CKD
Pearls of Wisdom: Optimizing Hyperkalemia Management in Patients with CKD
CME/CEPearls of Wisdom: Optimizing Hyperkalemia Management in Patients with CKD
0.25 credits
Matthew R. Weir, MD
Nihar Desai, MD
Ellie Kelepouris, MD, FACP, FAHA
0.25 creditsOptimizing AAV Outcomes: Maintenance Therapies
Optimizing AAV Outcomes: Maintenance Therapies
MinuteCE®Optimizing AAV Outcomes: Maintenance Therapies
0.75 program creditsBernhard Hellmich, MD
Silke R. Brix, MD, MRCP, SCPR
0.75 program creditsElevating Care for Patients With Severe Renal Disease in AAV
Elevating Care for Patients With Severe Renal Disease in AAV
MinuteCE®Elevating Care for Patients With Severe Renal Disease in AAV
0.75 program creditsSilke R. Brix, MD, MRCP, SCPR
Andreas Kronbichler, MD
0.75 program creditsManaging Patients With AAV in the Rheumatology Clinic
Managing Patients With AAV in the Rheumatology Clinic
MinuteCE®Managing Patients With AAV in the Rheumatology Clinic
0.75 program creditsAndreas Kronbichler, MD
Bernhard Hellmich, MD
0.75 program credits